Voice and Swallowing Outcomes Following Revision Anterior Cervical Spine Surgery
Launched by UNIVERSITY OF ALABAMA AT BIRMINGHAM · Nov 19, 2009
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how voice and swallowing abilities change after patients undergo revision anterior cervical spine surgery. If you're someone who has trouble swallowing (dysphagia) or speaking (dysphonia) and are planning to have this type of surgery, you might be eligible to participate. The trial is open to people aged 39 and older who are having this surgery again, but those with serious throat issues or certain vocal cord problems won't be included.
Participants in this study can expect to be monitored after their surgery to see how well they can swallow and speak. The goal is to understand how the surgery affects these important functions and to help improve care for future patients. If you join, you'll be contributing valuable information that could help others facing similar challenges. The trial is currently recruiting participants, so there’s still time to get involved.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients undergoing revision anterior cervical spine surgery
- Exclusion Criteria:
- • Primary pathology of the upper aero-digestive tract other than mild chronic pharyngitis, pre-existing vocal cord paralysis.
About University Of Alabama At Birmingham
The University of Alabama at Birmingham (UAB) is a prominent academic institution and research hub dedicated to advancing healthcare through innovative clinical trials. Renowned for its commitment to medical discovery and education, UAB conducts cutting-edge research across a wide array of disciplines, including oncology, cardiology, neurology, and public health. With a robust infrastructure for clinical research, UAB fosters collaboration among interdisciplinary teams, leveraging state-of-the-art facilities and resources to enhance the translation of scientific findings into effective treatments and interventions. As a leader in clinical research, UAB aims to improve patient outcomes and contribute to the broader medical community through rigorous trial design and implementation.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Birmingham, Alabama, United States
Patients applied
Trial Officials
William R Carroll, MD
Principal Investigator
University of Alabama at Birmingham
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials